How maternal antibodies can protect babies from cytomegalovirus
2022
Weill Cornell School of Medicine, New York, USA
Human cytomegalovirus (HCMV) is the most common congenital infection and a leading cause of stillbirth, neurodevelopmental impairment, and paediatric hearing loss worldwide. The development of a maternal vaccine or therapeutic to prevent congenital HCMV has been hindered by limited knowledge of the immune responses that protect against HCMV transmission in utero. To identify protective antibody responses, the researchers measured HCMV-specific IgG binding and antiviral functions in paired maternal and cord blood sera from HCMV-seropositive transmitting and non-transmitting mother-infant dyads identified via a large, US-based, public cord blood bank. They found that specific immunological responses and signalling cascades were associated with the risk of congenital HCMV infection. These data can guide future prospective studies on immune correlates against congenital HCMV transmission and inform HCMV vaccine and immunotherapeutic development.
Maternal Fc-mediated non-neutralizing antibody responses correlate with protection against congenital human cytomegalovirus infection
Sallie R. Permar
Added on: 12-02-2022
[1] https://www.jci.org/articles/view/156827[2] https://www.drugtargetreview.com/news/104277/research-reveals-how-maternal-antibodies-can-protect-babies-from-cytomegalovirus/?utm_source=Email+marketing&utm_medium=email&utm_campaign=DTR+-+Industry+Insight+-+Fusion+Antibodies+-+Antibodies+-+29.07.22&utm_term=How+to+select+the+best+combination+of+antibodies+to+treat+HIV&utm_content=https%3a%2f%2femails.drugtargetreview.com%2frussellpublishinglz%2f&gator_td=tCWdylyMr%2f90F%2fbBvRIVOYCNOufMxRhAaHPPx%2bQNVIHhUxjnBWNagb9HxuTqJlPO1VG%2blWPaPMQ95qTKCqJZDjx0STPo317UQLTn2RmYLv80gIMYNIom4hRXM3azsENmzz66lNQw%2f6%2ff3b%2b4KsVEoCmIblw4575RC%2buSotfg5Z%2blQ7vLqxZqxmCF2TUcVBofmntb3Y9X%2bem7z5PpHwrQoIE9edkzM1jNiZWTFYfHPXcGwurLuCvldwqxto5DIlX1JPdHCQVyHP1PBO%2bWrkasqg%3d%3d
